OFSEP researchers will be present at ECTRIMS 2019. Come and hear about their work! You can also meet the OFSEP coordination team at EDMUS stand, no. D32 and ask all the questions you may have. We look forward to seeing you there!

**Wednesday, 11 September 2019**

**13:45 - 15:15** Scientific Session 2: Safety assessment in the postapproval phase – real world evidence

- **Hall C**

**15:45 – 17:15** Scientific Session 3: DMT in RRMS

- **Hall A**
  - 94 - Big multiple sclerosis data network: marginal structural models confirm the long-term impact of DMTs on disability progression G. Luciano (Pescara, IT)

**15:45 – 17:15** Scientific Session 4: What determines the long-term outcome of MS?

- **Hall B**
  - 97 - Radiologically Isolated Syndrome: a 10-year follow-up study to identify factors predicting a clinical event, C. Lebrun-Frenay (Nice, FR)

**17:15 - 19:15** Poster session 1

- **P383** Opportunities and challenges for conducting research on Secondary Progressive Multiple Sclerosis across International Multiple Sclerosis registries through a research network collaboration, J. Hillert (Stockholm, SE)
- **P450** Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients' characteristics R. Casey (Lyon, FR)
- **P674** Incidence of relapses in patients with purified high dose biotin-treated progressive multiple sclerosis (IPBio-SeP study): a second intermediate analysis of a French, multicenter study, X. Moisset (Clermont-Ferrand, FR)

**Thursday, 12 September 2019**

**10:00 – 11:30** Scientific Session 7: How to achieve a structured assessment and quality assurance in MS care

- **Hall C**
  - 167 - To design, implement and sustain big data collection in MS H. Butzkueven (Melbourne, AU)

**16:15 - 17:15** Free Communication 5: MOG

- **Hall B**
  - 242 - MOG-antibodies and multiple sclerosis in adults: a large multicentre cross-sectional study, A. Cobol-Calvo (Lyon, FR)

**17:15 - 19:15** Poster session 2

- **P1034** Effectiveness of subcutaneous interferon beta-1a 22/44 μg versus teriflunomide in newly treated patients with multiple sclerosis. A study in a French nationwide cohort of multiple sclerosis: Observatoire Français de la Sclérose en Plaques (OFSEP) F. Rolot (Lyon, FR)
- **P1048** Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis, I. Roos (Melbourne, AU)
- **P1053** Therapeutic lag in relapsing multiple sclerosis, I. Roos (Melbourne, AU)

**Friday, 13 September 2019**

**08:30 – 10:00** Scientific Session 11: Registry-based MS research

- **Hall A**
  - 274 - Excess mortality in patients with relapsing-onset multiple sclerosis depends on age rather than disease duration: new insights from an innovative flexible model applied on French OFSEP data (Observatoire Français de la Sclérose en Plaques') E. Leray (Rennes, FR)

**12:15 - 14:15** Poster session 3

- **P1139** Clinical factors of conversion to progressive phase in relapsing-remitting multiple sclerosis patients within 11 years N. Derache (Caen, FR)
- **P1323** Compared CSF biomarker profile of AQP4-Ab, MOG-Ab and double seronegative NMOSD reveals specificities with potential therapeutic implications E. Thouvenot (Nîmes, FR)
- **P1381** Big Multiple Sclerosis Data – A registry basis for post authorization safety studies (PASS) for multiple sclerosis, J. Hillert (Stockholm, SE)
- **P1388** Long-term effectiveness, safety and tolerability with fingolimod treatment in patients with multiple sclerosis in real-world treatment settings in France: final results of the VIRGILE study, G. Castelnovo (Nîmes, FR)
- **P1418** Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis, S. Sharmin (Melbourne, AU)

**Let's go further...**

Do you want to find out more about OFSEP? To look at the cohort description? To see which data and biological samples are available for your projects? Please flash the QR code opposite or visit our website.

www.ofsep.org